LEADER 01420nam  2200385Ia 450 
001 9910699281803321
005 20230902162106.0
035   $a(CKB)5470000002401085
035   $a(OCoLC)471847531
035   $a(EXLCZ)995470000002401085
100   $a20091201d2007      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eANDAs, pharmaceutical solid polymorphism, chemistry, manufacturing and controls information
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2007]
215   $a1 online resource (10 pages) $ccharts
300   $a"OGD."
300   $a"July 2007."
517   $aGuidance for industry 
606   $aPolymorphism (Crystallography)
606   $aDrug factories$xGovernment policy$zUnited States
606   $aDrug stability$xGovernment policy$zUnited States
615  0$aPolymorphism (Crystallography)
615  0$aDrug factories$xGovernment policy
615  0$aDrug stability$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.).$bOffice of Generic Drugs.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699281803321
996   $aGuidance for industry$93434577
997   $aUNINA